Scottish no for Bayer's Nexavar prompts call for cancer drugs fund in Scotland
This article was originally published in Scrip
Executive Summary
The health technology assessment body for Scotland, the Scottish Medicines Consortium (SMC), has again rejected Bayer's Nexavar (sorafenib) for use on the Scottish NHS for treating hepatocellular carcinoma (HCC). The drug is available in England through the interim Cancer Drugs Fund, and critics of the SMC are now suggesting that Scotland too must set up a mechanism to address poor uptake of cancer treatment.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.